Article

Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant

2021-01-24

Abstract excerpt

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in millions of deaths worldwide and massive societal and economic burden. Recently, a new variant of SARS-CoV-2, known as B.1.1.7, was first detected in the United Kingdom and is spreading in several other countries, heightening public health concern and raising questions as to the resulting ef...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 07885945-6468-5f37-9acb-b4e021978132
DOI: 10.1101/2021.01.24.427991

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variantDOI 10.1101/2021.01.24.427991Read

Host directed therapies: COVID-19 and beyondSemantic proximity Read

A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antiviralsSemantic proximity Read

An Overview on Drug Evolution and Trials on Pandemic COVID-19 InfectionSemantic proximity Read

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.Semantic proximity Read

Current status and clinical outcomes of pharmacotherapies according to SARS-CoV-2 mutations in patients with mild-to-moderate COVID-19: a retrospective single center study.Semantic proximity Read

Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel StrategiesSemantic proximity Read

Approaches to the Potential Therapy of COVID-19: A General Overview from the Medicinal Chemistry PerspectiveSemantic proximity Read

Special Issue “Host Targeted Therapeutics Against Virus Infections”Semantic proximity Read

Discovery and Development of Safe-in-Man Broad-Spectrum Antiviral AgentsSemantic proximity Read

Broad-Spectrum Antiviral Strategies and Nucleoside AnaloguesSemantic proximity Read

Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2Semantic proximity Read

Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5Semantic proximity Read